Literature DB >> 24444656

Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics.

Sharad Sharma1, Hang-Ping Yao2, Yong-Qing Zhou3, Jianwei Zhou4, Ruiwen Zhang5, Ming-Hai Wang6.   

Abstract

Targeted inhibition of MET/RON signaling by tyrosine kinase inhibitor BMS-777607 for cancer treatment is currently under clinical trials. We have previously shown that BMS-777607 induces chemoresistance in vitro by causing polyploidy, which hampers therapeutic efficacy. Here, we studied polyploidy-associated senescence induced by BMS-777607 in breast cancer cells and its prevention by mTOR inhibitor AZD8055, leading to increased chemosensitivity. In breast cancer T-47D and ZR-75-1 cells, BMS-777607 induced phenotypic changes including enlarged cellular size, flattened morphology, increased DNA content, and activity of senescence-associated β-galactosidase. These changes were accompanied by increased p21/WAF1 expression and decreased Retinoblastoma Ser(780) phosphorylation, indicating that BMS-777607 induces not only polyploidy but also senescence. The appearance of senescence was associated with polyploidy in which β-galactosidase is exclusively expressed in polyploid cells. Survivin expression was increased in polyploid/senescent cells as analyzed by Western blotting. Increased survivin accumulated both in the nucleus and cytoplasm and dissociated with condensed DNA and mitotic spindle at the metaphase. Abnormal accumulation of survivin also rendered polyploid/senescent cells insensitive to cytotoxic activities of YM155, a DNA damaging agent with a suppressive effect on survivin gene transcription. AZD8055, a specific mTOR inhibitor, effectively prevented BMS-777607-induced polyploidy and senescence and restored survivin expression and its nuclear localization to normal levels. Although a synergism was not observed, BMS-777607 plus AZD8055 increased cancer cell sensitivity toward different cytotoxic chemotherapeutics. In conclusion, BMS-777607-induced chemoresistance is associated with cell polyploidy and senescence. Inhibition of mTOR signaling by AZD8055 prevents BMS-777607-induced polyploidy/senescence and increases breast cancer cell chemosensitivity.
Copyright © 2013 Federation of European Biochemical Societies. All rights reserved.

Entities:  

Keywords:  Breast cancer; Chemosensitivity; Polyploidy; Receptor tyrosine kinase; Senescence; Small molecule inhibitor; mTOR signaling

Mesh:

Substances:

Year:  2014        PMID: 24444656      PMCID: PMC5528636          DOI: 10.1016/j.molonc.2013.12.014

Source DB:  PubMed          Journal:  Mol Oncol        ISSN: 1574-7891            Impact factor:   6.603


  50 in total

1.  Survivin and escaping in therapy-induced cellular senescence.

Authors:  Qin Wang; Peter C Wu; Rachel S Roberson; Belinda V Luk; Iana Ivanova; Elizabeth Chu; Daniel Y Wu
Journal:  Int J Cancer       Date:  2010-05-25       Impact factor: 7.396

Review 2.  mTOR in aging, metabolism, and cancer.

Authors:  Marion Cornu; Verena Albert; Michael N Hall
Journal:  Curr Opin Genet Dev       Date:  2013-01-11       Impact factor: 5.578

Review 3.  Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer.

Authors:  Nuzhat Ahmed; Khalid Abubaker; Jock Findlay; Michael Quinn
Journal:  Curr Cancer Drug Targets       Date:  2010-05       Impact factor: 3.428

4.  Disabling the mitotic spindle and tumor growth by targeting a cavity-induced allosteric site of survivin.

Authors:  A Berezov; Z Cai; J A Freudenberg; H Zhang; X Cheng; T Thompson; R Murali; M I Greene; Q Wang
Journal:  Oncogene       Date:  2011-09-05       Impact factor: 9.867

5.  Down-regulation of wild-type p53-induced phosphatase 1 (Wip1) plays a critical role in regulating several p53-dependent functions in premature senescent tumor cells.

Authors:  Elvira Crescenzi; Zelinda Raia; Francesco Pacifico; Stefano Mellone; Fortunato Moscato; Giuseppe Palumbo; Antonio Leonardi
Journal:  J Biol Chem       Date:  2013-04-23       Impact factor: 5.157

6.  Altered expression of the RON receptor tyrosine kinase in various epithelial cancers and its contribution to tumourigenic phenotypes in thyroid cancer cells.

Authors:  M-H Wang; W Lee; Y-L Luo; M T Weis; H-P Yao
Journal:  J Pathol       Date:  2007-12       Impact factor: 7.996

7.  Ectopic Tbx2 expression results in polyploidy and cisplatin resistance.

Authors:  E Davis; H Teng; B Bilican; M I Parker; B Liu; S Carriera; C R Goding; S Prince
Journal:  Oncogene       Date:  2007-08-13       Impact factor: 9.867

8.  Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents.

Authors:  Sharad Sharma; Jun-Ying Zeng; Chun-Mei Zhuang; Yong-Qing Zhou; Hang-Ping Yao; Xing Hu; Ruiwen Zhang; Ming-Hai Wang
Journal:  Mol Cancer Ther       Date:  2013-03-06       Impact factor: 6.261

9.  Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models.

Authors:  Takahito Nakahara; Aya Kita; Kentaro Yamanaka; Masamichi Mori; Nobuaki Amino; Masahiro Takeuchi; Fumiko Tominaga; Isao Kinoyama; Akira Matsuhisa; Masafumi Kudou; Masao Sasamata
Journal:  Cancer Sci       Date:  2011-01-12       Impact factor: 6.518

10.  Sepantronium bromide (YM155) induces disruption of the ILF3/p54(nrb) complex, which is required for survivin expression.

Authors:  Tomohiro Yamauchi; Naoto Nakamura; Masashi Hiramoto; Masatoshi Yuri; Hiroyuki Yokota; Masanori Naitou; Masahiro Takeuchi; Kentaro Yamanaka; Aya Kita; Takahito Nakahara; Isao Kinoyama; Akira Matsuhisa; Naoki Kaneko; Hiroshi Koutoku; Masao Sasamata; Masato Kobori; Masao Katou; Shuichi Tawara; Shigeki Kawabata; Kiyoshi Furuichi
Journal:  Biochem Biophys Res Commun       Date:  2012-07-27       Impact factor: 3.322

View more
  8 in total

Review 1.  TYRO3: A potential therapeutic target in cancer.

Authors:  Pei-Ling Hsu; Jonathan Jou; Shaw-Jenq Tsai
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-02

2.  Prevention of BMS-777607-induced polyploidy/senescence by mTOR inhibitor AZD8055 sensitizes breast cancer cells to cytotoxic chemotherapeutics.

Authors:  Sharad Sharma; Hang-Ping Yao; Yong-Qing Zhou; Jianwei Zhou; Ruiwen Zhang; Ming-Hai Wang
Journal:  Mol Oncol       Date:  2014-01-02       Impact factor: 6.603

Review 3.  The MST1R/RON Tyrosine Kinase in Cancer: Oncogenic Functions and Therapeutic Strategies.

Authors:  Alex Cazes; Betzaira G Childers; Edgar Esparza; Andrew M Lowy
Journal:  Cancers (Basel)       Date:  2022-04-18       Impact factor: 6.575

4.  The role of stearoyl-coenzyme A desaturase 1 in clear cell renal cell carcinoma.

Authors:  Hui Wang; Yujian Zhang; Yongning Lu; Jiajia Song; Min Huang; Jin Zhang; Yiran Huang
Journal:  Tumour Biol       Date:  2015-07-31

5.  A Selective β-Catenin-Metadherin/CEACAM1-CCL3 Axis Mediates Metastatic Heterogeneity upon Tumor-Macrophage Interaction.

Authors:  Sally K Y To; Maggie K S Tang; Yin Tong; Jiangwen Zhang; Karen K L Chan; Philip P C Ip; Jue Shi; Alice S T Wong
Journal:  Adv Sci (Weinh)       Date:  2022-04-11       Impact factor: 17.521

Review 6.  Targeting tumor cell senescence and polyploidy as potential therapeutic strategies.

Authors:  Tareq Saleh; Valerie J Carpenter; Sarah Bloukh; David A Gewirtz
Journal:  Semin Cancer Biol       Date:  2020-12-20       Impact factor: 17.012

7.  Polyploidy Formation in Doxorubicin-Treated Cancer Cells Can Favor Escape from Senescence.

Authors:  Grazyna Mosieniak; Malgorzata A Sliwinska; Olga Alster; Anna Strzeszewska; Piotr Sunderland; Malgorzata Piechota; Halina Was; Ewa Sikora
Journal:  Neoplasia       Date:  2015-12       Impact factor: 5.715

Review 8.  Role of the Circadian Clock "Death-Loop" in the DNA Damage Response Underpinning Cancer Treatment Resistance.

Authors:  Ninel Miriam Vainshelbaum; Kristine Salmina; Bogdan I Gerashchenko; Marija Lazovska; Pawel Zayakin; Mark Steven Cragg; Dace Pjanova; Jekaterina Erenpreisa
Journal:  Cells       Date:  2022-03-03       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.